Pacira Biosciences Inc (NASDAQ:PCRX) Shares Acquired by AlphaCrest Capital Management LLC

AlphaCrest Capital Management LLC grew its position in shares of Pacira Biosciences Inc (NASDAQ:PCRX) by 94.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 17,340 shares of the company’s stock after purchasing an additional 8,440 shares during the quarter. AlphaCrest Capital Management LLC’s holdings in Pacira Biosciences were worth $660,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the company. Rehmann Capital Advisory Group boosted its stake in Pacira Biosciences by 28.5% during the 4th quarter. Rehmann Capital Advisory Group now owns 2,217 shares of the company’s stock worth $95,000 after purchasing an additional 492 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Pacira Biosciences by 22.3% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,950 shares of the company’s stock worth $127,000 after purchasing an additional 538 shares during the last quarter. Raymond James Financial Services Advisors Inc. boosted its stake in Pacira Biosciences by 12.2% during the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 5,602 shares of the company’s stock worth $241,000 after purchasing an additional 610 shares during the last quarter. Legal & General Group Plc boosted its stake in Pacira Biosciences by 7.3% during the 4th quarter. Legal & General Group Plc now owns 16,652 shares of the company’s stock worth $717,000 after purchasing an additional 1,129 shares during the last quarter. Finally, Parametrica Management Ltd boosted its stake in Pacira Biosciences by 21.6% during the 4th quarter. Parametrica Management Ltd now owns 6,398 shares of the company’s stock worth $275,000 after purchasing an additional 1,138 shares during the last quarter. 99.13% of the stock is owned by hedge funds and other institutional investors.

Several research analysts have recently weighed in on the stock. Wedbush set a $85.00 price target on shares of Pacira Biosciences and gave the company a “buy” rating in a research report on Friday. Barclays assumed coverage on shares of Pacira Biosciences in a research report on Tuesday, June 11th. They set an “overweight” rating and a $52.00 price target on the stock. Zacks Investment Research raised shares of Pacira Biosciences from a “hold” rating to a “buy” rating and set a $47.00 price target on the stock in a research report on Friday, May 31st. Mizuho raised shares of Pacira Biosciences from an “underperform” rating to a “neutral” rating and boosted their price target for the company from $29.00 to $38.00 in a research report on Monday, May 6th. Finally, BMO Capital Markets set a $46.00 price target on shares of Pacira Biosciences and gave the company a “hold” rating in a research report on Friday, May 3rd. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and nine have assigned a buy rating to the company. Pacira Biosciences has an average rating of “Hold” and a consensus price target of $54.53.

In related news, insider Richard Scranton sold 15,510 shares of the company’s stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $43.21, for a total value of $670,187.10. Following the completion of the transaction, the insider now directly owns 23,111 shares of the company’s stock, valued at $998,626.31. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Lauren Bullaro Riker sold 2,126 shares of the stock in a transaction that occurred on Monday, June 10th. The shares were sold at an average price of $44.28, for a total value of $94,139.28. Following the completion of the sale, the vice president now directly owns 10,042 shares of the company’s stock, valued at $444,659.76. The disclosure for this sale can be found here. Insiders have sold 44,875 shares of company stock worth $1,934,674 over the last 90 days. Insiders own 5.80% of the company’s stock.

NASDAQ:PCRX traded down $0.94 on Monday, reaching $42.55. 458,768 shares of the company’s stock were exchanged, compared to its average volume of 592,434. The company has a quick ratio of 7.83, a current ratio of 8.62 and a debt-to-equity ratio of 0.99. The stock has a market cap of $1.80 billion, a price-to-earnings ratio of 146.72, a price-to-earnings-growth ratio of 2.45 and a beta of 1.14. The business has a fifty day simple moving average of $43.71. Pacira Biosciences Inc has a 52-week low of $31.51 and a 52-week high of $55.00.

Pacira Biosciences (NASDAQ:PCRX) last released its earnings results on Thursday, May 2nd. The company reported $0.22 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.20. Pacira Biosciences had a net margin of 2.10% and a return on equity of 6.78%. The firm had revenue of $91.31 million for the quarter, compared to analyst estimates of $92.13 million. During the same period in the prior year, the firm earned $0.02 earnings per share. The business’s quarterly revenue was up 22.4% compared to the same quarter last year. As a group, research analysts anticipate that Pacira Biosciences Inc will post 0.77 EPS for the current year.

Pacira Biosciences Company Profile

Pacira BioSciences, Inc provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The company develops products based on its proprietary DepoFoam product delivery technology that encapsulates drugs without altering their molecular structure.

Featured Story: Different Types of Derivatives

Institutional Ownership by Quarter for Pacira Biosciences (NASDAQ:PCRX)

Receive News & Ratings for Pacira Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.